a validated equine biomarker of endotoxemia in the flunixin meglumine group. Both groups had a sim- ilar prevalence of clinical endotoxemia signs (P0.30) and only a 1.4-fold relative risk of non- survival in the flunixin meglumine group (P0.54).
4. Discussion
In SISO patients, flunixin meglumine or firocoxib effectively controls postoperative pain and heart rate, but firocoxib is associated with a reduced risk of elevated sCD14.
Acknowledgments
Funding was provided by Grayson-Jockey Club Re- search Foundation, Lexington, KY, USA. Firocoxib was provided by Merial, Inc.
Declaration of Ethics
The Authors have adhered to the Principles of Vet- erinary Medical Ethics of the AVMA.
Conflict of Interest The Authors have no conflicts of interest.